MESO Q3 2022 Earnings — Mesoblast Limited Revenue & Financial Results | Market Cap Arena

MESOMesoblast Limited

$2B

Q3 2022 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$2M+5.1% YoY

Gross Profit

-$12M-588.2% margin

Operating Income

-$19M-961.7% margin

Net Income

-$21M-1059.3% margin

EPS (Diluted)

$-0.33

QoQ Revenue Growth

-15.6%

Cash Flow

Operating Cash Flow

-$15M

Free Cash Flow

-$16M

Stock-Based Comp.

$2M

Balance Sheet

Total Assets

$682M

Total Liabilities

$165M

Stockholders' Equity

$517M

Cash & Equivalents

$76M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$2M	$2M	+5.1%
Gross Profit	-$12M	-$18M	+33.8%
Operating Income	-$19M	-$26M	+25.3%
Net Income	-$21M	-$27M	+19.7%